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There is in fact a true law - namely, right reason - which is in accordance 
with nature, applies to all men, and is unchangeable and eternal. 
 
Marcus Tullius Cicero 
 
 

 ABSTRACT 
Individuals vary widely in their response to drug treatment. After receiving doses of a drug that are recommended based on a 
population average, some patients could have an insufficient response, whereas others may experience adverse effects. Of the 
many factors causing variability in drug response across individuals, genetic polymorphism of drug-metabolizing enzymes is 
deemed to be one of the valuable independent predictors of this variability. CYP2C19 is an important polymorphically expressed 
enzyme known to catalyze the metabolism of several widely prescribed drugs, including omeprazole, warfarin (R-enantiomer), 
and citalopram/escitalopram. The impact of CYP2C19 polymorphisms on the pharmacokinetics (PK) of its substrates and 
corresponding clinical relevance are of great interest. 
The aim of this thesis is to investigate the influence of CYP2C19 polymorphisms on PK and pharmacodynamics (PD) of 
clinically important CYP2C19 substrates (e.g., omeprazole, citalopram, and warfarin), and to advance the understanding of their 
inter-individual variability in drug therapy. We quantified the effect of functional CYP2C19 allele variants, including the gain-of-
function allele (CYP2C19*17), on drug exposure and response in order to facilitate personalized dose selection.  
In Paper I, we studied the disposition of omeprazole and its effect on plasma gastrin levels following single and multiple doses in 
the three phenotype groups (extensive metabolisers [EMs], intermediate metabolisers [IMs], and poor metabolisers [PMs]) of S-
mephenytoin hydroxylation. When 20 mg of omeprazole was given orally for 8 days on a once-daily (QD) regimen, the relative 
AUC ratios in EMs, IMs, and PMs were 1:5.3:13.1. Differences in the plasma gastrin levels (used as a PD marker) were also 
significant between the three groups and the increase was in an omeprazole-concentration-dependent fashion. Suitability of 
omeprazole as a probe for CYP2C19 was also explored. The metabolic ratio (MR) of omeprazole was correlated significantly 
with S/R ratio of mephenytoin. 
Paper II further studied the use of omeprazole as a probe for CYP2C19 activity in a population of 160 unrelated Swedish 
subjects. There was a close correlation between MRs of omeprazole and S/R ratios of mephenytoin. A good agreement was also 
demonstrated between the CYP2C19 phenotypes (both by omeprazole and mephenytoin) and the genotype with respect to 
CYP2C19*2, indicating that genotype is a valid predictor of CYP2C19 activity. Since omeprazole is a substrate for both 
CYP2C19 and CYP3A4, the potential advantage also includes using it as a dual-substrate probe. 
In Paper III, we used omeprazole as a dual substrate probe to assess the potential for PK interactions between carbamazepine 
(CBZ) and omeprazole and, particularly, the inducibility of CYP3A4 and CYP2C19 by CBZ. Both omeprazole and 
hydroxyomeprazole decreased by approximately 40% in mean AUC after coadministration of omeprazole with CBZ, while the 
sulphone metabolite increased by 44%. None of the AUC changes were statistically significant due to the large variation and 
small sample size. A significant decrease in the AUC ratio between hydroxyomeprazole and sulphone metabolite was observed, 
suggesting induction was more pronounced for CYP3A4 than for CYP2C19. 
The potential contribution of the CYP2C19 genotypes on R-warfarin clearance with special focus on the gain-of-function allele 
(CYP2C19*17) was the primary objective for Paper IV. Compared to CYP2C19*2 carriers, the mean R-warfarin clearance 
increased by 32% in CYP2C19*17 carriers, 26% in the CYP2C19*2/*17 genotype, and 11% in CYP2C19*1/*1 genotype. 
CYP2C19 genotypes also contributed to the variability of INR/daily dose where VKORC1 (Vitamin K epoxide reductase 
subcomplex 1) and CYP2C9 genotypes are the major determinants in warfarin treatment. About 52% of variance can be 
explained by the combinations of VKORC1, CYP2C9, CYP2C19, age, gender, and bodyweight, of which CYP2C19 genotypes 
accounted for 7%.  
Paper V pooled data from16 published studies to quantify the effect of functional CYP2C19 allele variants on 
citalopram/escitalopram exposure by means of meta-analysis. Compared to subjects with EM/EM (*1/*1) genotype, the exposure 
to (es)citalopram increased by 95% in the PM/PM (*2/*2, *2/*3, or *3/*3), 30% in the EM/PM (*1/*2 or *1/*3), and 25% in the 
UM (ultrarapid metaboliser)/PM (*17/*2 or *17/*3) groups. In contrast, the exposure to (es)citalopram decreased by 36% in the 
UM/UM (*17/*17) and by 14% in the UM/EM (*17/*1) groups. All functional CYP2C19 genotypes showed significant effects 
on citalopram/escitalopram exposure compared to the CYP2C19*1/*1 genotype. 
In conclusion, there are significant effects of CYP2C19 polymorphisms on PK and PD of drugs that are metabolized by the 
CYP2C19 enzyme. The results of this thesis demonstrate that CYP2C19 genotype is an important independent predictor of the 
exposure to omeprazole, R-warfarin, and citalopram/escitalopram. Increased knowledge and understanding of inter-individual 
variability, genotype-phenotype correlation, and the impact of CYP2C19 polymorphisms on clinical practice are helpful in 
optimizing personalized drug therapy.  
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1 INTRODUCTION 
PRIMER 
In early spring of 1992, Professor Ya-qing Lou at Beijing Medical University and her group 
collaborated with a research team at Karolinska Institutet led by Dr. Leif Bertilsson. The goal 
of his project was to compare debrisoquin and S-mephenytoin hydroxylation between two 
large population samples of native Chinese and Swedish healthy subjects. Being an associate 
researcher at the time, I assisted Prof. Lou in recruiting healthy volunteers. It turned out that 
two of my close family members participated in the study and both were identified as PMs of 
S-mephenytoin. This early touch on the concept of CYP2C19 polymorphism at least partially 
accounts for my long journey into this interesting area of research. 
1.1  DRUG METABOLISM AND CHARACTERIZATION  
Most drugs are primarily eliminated through metabolism processes. Drug metabolism is an 
enzymatic conversion of one chemical compound into another [1]; the term “metabolite” 
describes the product formed by metabolism. The metabolism process is commonly divided 
into two phases of biochemical reactions, i.e. Phase 1 and Phase 2 reactions. Phase 1 
reactions transform the parent drug into a more polar metabolite by oxidation, reduction, or 
hydrolysis, a vital step before the drug can be excreted into the urine or bile. Inactive 
prodrugs can also be converted to the active molecule through Phase 1 reaction. Therefore, 
metabolites might be pharmacologically and toxicologically inactive, less active, equally 
active, or more active than the parent molecule. Phase 2 reactions, on the other hand, couple 
the drug or its polar metabolite with an endogenous substrate (for example UDP glucuronic 
acid, amino acid, sulfate, or acetate). Liver is the main organ for drug metabolism, but the 
metabolism processes can also occur in other organs, such as the intestines, kidney, and 
lungs.  
To characterize the metabolic clearance of drugs, the pharmacokinetic (PK) properties of 
parent drugs and their metabolite(s), and the potential for metabolism based drug-drug 
interactions (DDI), a series of drug metabolism studies are usually conducted with a 
combination approach of in vitro and in vivo experiments [2]. 
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1.1.1 Prediction of metabolic clearance using in vitro approach 
In vitro experiments provide valuable information to the clearance mechanism for drugs 
and drug candidates. In the past decades, the knowledge of drug-metabolizing enzymes 
has increased tremendously so that prediction of the metabolic fate of drug candidates 
in human becomes possible. Typically, the in vitro experimental methods refer to the 
incubation with human liver microsomes, recombinant single expressed human 
isoforms (expressed enzymes), and cryopreserved or freshly isolated hepatocytes. The 
approach is employed to address a variety of questions, such as which enzymes are 
responsible for the metabolism of the drug? Is the drug candidate metabolically stable? 
Is there any human unique metabolite which was not tested in animal toxicity studies? 
Metabolic stability, inhibition of drug-metabolizing enzymes and identification of 
specific enzymes responsible for the metabolism of a drug are the classic examples of 
utilizing in vitro approaches. To predict the clearance in humans and to understand the 
contribution of individual enzymes to the total clearance, the drug candidates can be 
incubated with single expressed human enzymes, pooled human liver microsomes, or 
hepatocytes with and without enzyme-specific chemical inhibitors. Metabolic clearance 
(CLint), obtained based on the disappearance of the parent drug from the incubation 
mixture over incubation time, is used to estimate the hepatic clearance. The 
extrapolation from in vitro to in vivo is performed by factoring in amount of 
enzyme/tissue used in the incubation and the weight of the liver, assuming the well-
stirred model for hepatic clearance. If the concentrations of test compound rapidly 
decline over time in systems expressing a specific enzyme (i.e. showing a high CLint) 
and the reaction can be inhibited by an established chemical inhibitor, it is likely that 
the enzyme plays a role in the metabolism of the compound tested. Consequently, 
further evaluation of this compound in clinical setting would be considered.  
1.1.2 Evaluation of drug metabolism using in vivo approach 
Clinical evaluations are important to fully characterize the drug metabolism in humans. 
The metabolic profiles and elimination pathways are routinely generated from ADME 
(absorption, distribution, metabolism, excretion) studies in healthy subjects using radio-
labeled drug. The ADME study also provides information on the total radioactivity 
recovered in urine, feces, and bile (known as mass balance) as well as quantitative 
3 
metabolites measurement relative to the parent drug in several matrices, typically in 
blood, urine, and bile. 
Clinically relevant DDIs have been acknowledged as a cause of large inter-individual 
variability in PK and drug response. According to Furuta et al [3], AUCs of omeprazole 
increased 2.1-2.3 fold after coadministration of omeprazole with clarithromycin. The two 
drugs are frequently prescribed together to treat patients who have Helicobacter pylori 
infection and duodenal ulcer. When investigating DDIs in clinical trials, a typical study 
design is open-label, single-dose (multiple-dose for inducer test), two-way interaction in 
healthy subjects. The established substrates, inhibitors and/or inducers for the enzyme in 
question can be used as probe drugs in DDI evaluation. 
1.1.3 In vitro-in vivo correlation  
Human liver microsomes and hepatocytes have been reliably used to study inhibition 
mechanism and to predict human clearance. Due to various reasons, the discrepancy 
between in vitro and in vivo happens. For example, if standard assumptions that used for 
in vitro incubation are no longer applicable in humans, poor prediction outcome would be 
anticipated. Overall, whether or not to conduct an in vivo study is based on the 
quantitative measurement of the enzyme contributed to one pathway and the portion of 
metabolite formed from that particular pathway. The decision tree for metabolism-based-
DDI-study, presented by US Food and Drug Administration (FDA) [4], is an example of 
a comprehensive approach incorporating cutting edge technology of in vitro experiments, 
modeling, and clinical trials. 
The common practice for estimating DDI liability in human is to start with assessing the 
worst case-scenario by coadministration of the drug studied with a strong inhibitor. If the 
exposure to the drug with or without coadministration (e.g. AUC ratio) is within the 
predefined confidence interval of 0.8-1.25, the absence of a DDI for the metabolic 
pathway is demonstrated. On the contrary, a positive finding, i.e., confidence interval 
outside pre-specified interval, may lead to dosage adjustment, restrictions and cautions to 
concomitant use, additional therapeutic monitoring, or other measures to mitigate risk. As 
an alternative, physiologically-based pharmacokinetic (PBPK) modeling can be 
employed to simulate the trial and predict the clinical outcomes [4].  
4 
1.2 METABOLIC ENZYMES 
The number of enzymes involved in drug metabolism reactions is large and govern 
catelyzing phase 1 oxidation, reduction, and hydrolysis reactions. Of the enzymes playing 
a role in the biotransformation of various pharmaceutical products, the dominant enzyme 
system is cytochrome P450 (CYP450) superfamily, accounting for 75% of reactions. 
UDP-glucuronosyl-transferases catelyze ~20% of the reactions. 
1.2.1 Cytochrome P450 and nomenclature 
Many cytochrome P450 enzymes have specific roles in the metabolism of steroids, 
eicosanoids and fat-soluble vitamins while about 1/4 of CYP450 enzymes are involved in 
the metabolism of xenobiotics including many drugs. CYP450 enzymes convert 
lipophilic drugs to hydrophilic metabolites prior to the drugs’ excretion, and are 
considered of great significance in the overall biological handling of drugs.  
A nomenclature system for P450 enzymes was implemented in 1987 based on the degree 
of similarity of primary amino acid sequences [5]. The members of separate gene families 
have ≤ 40% amino acid similarity (e.g. CYP1 vs. CYP2), while ≥ 59% similarity are 
assigned to the same gene subfamily (e.g. CYP2C). In other words, human loci are 
indicated by CYP followed by an Arabic number specifying the P450 family (e.g., 
CYP2), a letter for the subfamily (e.g., CYP2C) and an Arabic numeral for the gene, for 
example CYP2C19. The nomenclature system, however, depends neither on the function 
of P450 enzyme nor on the reactions they catalyze.  
Of more than 100 CYP450 isozymes, only a dozen are responsible for the metabolism of 
the majority of drugs. CYP3A4/5 accounts for ~ 29% of the CYP450 content in human 
liver and 30% by reactions, based on data gathered from 248 clinically used drugs [6], [7] 
metabolized by the major CYP450 sub-families. The CYP2C subfamily accounts for 
~18% by liver content and 24% by reactions, respectively, followed by CYP1A2 (~13% 
by liver content, 9% by reactions), CYP2E1 (7%, 3%), CYP2A6 (4 %, 3%), CYP2B6 
(<1%, 7 %), and CYP2D6 (2%, 20%). The fractions of contribution of major isoforms in 
drug metabolism by reactions based on these 248 clinically used drugs are presented in 
Figure 1. 
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Figure 1. Fraction of contribution of CYP3A4/5, CYP1A2, CYP2B6, CYP2D6, CYP2C and further 
breakdown of CYP2C to CYP2C8, CYP2C9, and CYP2C19 in drug metabolism (based on 248 
clinically used drugs). 
1.2.2 CYP2C subfamily 
The CYP2C subfamily metabolizes approximately 20-25% of clinically used drugs. 
Four enzymes are identified in the CYP2C subfamily, namely CYP2C8, CYP2C9, 
CYP2C18, and CYP2C19. Of the subfamily CYP2C8, CYP2C9, and CYP2C19 are of 
clinical importance. The CYP2C enzymes generally have broad and overlapping 
substrate specificities. Some of them, however, demonstrated high activity against 
steroids, for example testosterone [8]. The CYP2C enzymes are also reported in 
developmentally regulated and sex-specific expression in animals [8], calling for 
cautions when using animal models to predict human responses. At the protein level, 
CYP2C9 is the highest expressed member in the 2C subfamily, comparable to CYP3A4 
[9],[10]. The expression of CYP2C19 is 10-fold lower than that of CYP2C9. Despite 
the low expression level relative to CYP2C9, CYP2C19 remains an important 
polymorphically expressed CYP isoforms, participating in the metabolism of many 
widely prescribed drugs including omeprazole, citalopram, diazepam, and clopidogrel. 
1.2.3 CYP2C19 enzyme 
The CYP2C19 enzyme is a protein of 490 amino acids which binds to substrates that 
are generally neutral or weakly basic molecules. The drugs metabolized by CYP2C19 
enzyme are classified as CYP2C19 substrates. Of these, the most commonly known 
substrates of CYP2C19 include proton pump inhibitors (PPIs: omeprazole, 
lansoprazole), certain antidepressants (citalopram/escitalopram, imipramine), 
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antiepileptics (diazepam, mephenytoin), the antimalarial drug proguanil, the β-
adrenoceptor blocker propranolol and the antiplatelet drug clopidogrel. 
CYP2C19 inhibition is observed with a number of molecules that bind to the enzyme and 
decrease the rate of substrate turnover. A few strong inhibitors of CYP2C19 are listed in 
FDA’s guidance (fluconazole, fluvoxamine, ticlopidine), but none of them are CYP2C19 
specific [4]. The mechanism of inhibition can be divided into reversible and irreversible 
inhibition (also known as time-dependent inhibition). Characterization of inhibitors are 
typically performed using in vitro methods [11], [12], [13] to generate IC50 or Ki. 
Prediction of likelihood of inhibition based on in vitro IC50 or Ki sometimes can be 
limited because the in vitro human tissues including hepatocytes do not represent true 
human physiological conditions. The clinical assessment of inhibition is, therefore, the 
most powerful approach, especially when studies are performed within the clinical 
relevance context. To study CPY2C19 inhibition, omeprazole can be used as a diagnostic 
probe in humans. Although it is a moderate inhibitor as classified by FDA, omeprazole 
has been proved to be a reliable and sensitive probe of CYP2C19.  
The CYP2C19 enzyme is also inducible. If enzyme activity or the total amount of 
enzyme is increased, an elevation of intrinsic metabolic clearance is anticipated. From a 
PK perspective, the victim of enzyme induction is associated with reduced AUC, Cmax, 
Cmin (trough concentration) and elimination half-life. The mechanism of induction 
involves nuclear hormone receptors, i.e. constitutive androstane receptor (CAR) [14], 
pregnane X receptor (PXR) [15], and estrogen response element (ESE) [16], [17]. 
Rifampicin, a potent inducer of CYP2C19 in humans, has been reported as a classic 
ligand to PXR, initiating transcription of mRNA and production of active enzyme. The 
induction of enzyme activity is concentration-dependent and less than the induction of 
transcription mRNA level [18], [19]. Compared to CYP3A4, the induction of CYP2C19 
activity is moderate. However, if a drug is metabolized by CYP2C19 and CYP3A4, both 
are induced by PXR (rifampicin), and the effect of induction can be additive, leading to a 
clinically significant interaction.  
1.3 CYP2C19 POLYMORPHISM  
Polymorphism has been employed to describe a trait that appears in a population as two or 
more phenotypes. It was defined by Vogel and Motulsky [20]: “A polymorphism is a 
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Mendelian or monogenic trait that exists in the population in at least two phenotypes (and 
presumable at least two genotypes), neither of which is rare - that is neither of which occurs 
with a frequency of less than 1-2%.” 
1.3.1 History of CYP2C19 polymorphism 
The polymorphism of CYP2C19 is also known as “S-mephenytoin polymorphism” 
because CYP2C19 metabolizes S-mephenytoin to 4’-OH-mephenytoin. In the late 1940s, 
mephenytoin was introduced onto the market as an anticonvulsant agent administered as a 
1:1 racemic mixture of the S - and R-enantiomers. In the 1970s, Adrian Küpfer, a Ph.D. 
student at the University of Berne, worked on an enantiomer project as part of his thesis 
and discovered the stereo-selective metabolism of mephenytoin in dogs [21]. Later, 
druing his postdoctorate training at Vanderbilt University, Küpfer and coworkers found 
the steroselectivity of S-mephenytoin metabolism in human subjects [22]. In this human 
study, one of the healthy volunteers complained of severe sedation after receiving a low 
dose of mephenytoin that had no effect on other individuals. Tracking the radio-labeled 
pseudo-racemic mephenytoin in urine samples, Küpfer et al. noticed a pronounced 
reduction of the 4’-OH-mephenytoin formed in this subject relative to others, suspecting 
polymorphism of drug hydroxylation for mephenytoin [23], [24]. A family study 
followed revealing a genetic basis for the impaired capability of 4’-OH-mephenytoin 
formation [25], [21]. Inaba and coworkers recruited five poor metabolisers and 28 
relatives of the five PM proband, and clearly demonstrated that the pattern of deficient 
mephenytoin hydroxylation was an autosomal recessive trait [26]. 
The findings of the polymorphism and its genetic basis powered extensive research in the 
field. At the beginning, CYP2C9 was thought to be the major enzyme responsible for the 
formation of 4’-OH-mephenytoin. However, cDNA expressions showed negative results 
on all of the allelic variants of CYP2C9 toward S-mephenytoin, including a sample from 
the “mythical poor metaboliser” [27], [28], [29], [30]. The first positive sign was 
observed in purified protein by Wrighton et al [31], discovering an association between 
the hepatic content of this protein and the activity of S-mephenytoin hydroxylase. In 
1994, Wrighton’s group and Goldstein’s group independently identified that CYP2C19 
was primarily responsible for mephenytoin 4’-hydroxylation using immunoblot analysis 
[32] and yeast cDNA expression system [30], respectively. 
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1.3.2 Phenotyping of CYP2C19 
CYP2C19 is one of the most studied drug-metabolizing enzymes that are 
polymorphically expressed in humans. When a polymorphism is involved in drug 
metabolism, individuals can be classified as either extensive metaboliser (EM) or poor 
metaboliser (PM) of a certain drug. In the case of CYP2C19, PM refers to the individual 
who lacks CYP2C19 enzyme activity based on phenotyping results. 
Phenotyping methods comprise administration of probe drugs and quantization of the 
drugs and metabolites in plasma or urine to determine enzyme activity in the 
populations tested. A great deal of effort has been made to find proper phenotyping 
methods which accurately characterize the enzyme function. A desirable probe and 
testing procedure include the following: 1) safe without side effects at the dose used; 2) 
mainly metabolized by the enzyme that is phenotyped; 3) available on the market; 4) 
easily applicable in operation including a simple and robust analytical assay; 5) 
relatively inexpensive. With respect to CYP2C19 phenotyping, the mephenytoin S/R 
ratio in urine collected during the 8 hours post dose (if possible, extend to 8-24 and 24-
32 hours collection) has been used for many years [33], [34]. Attributing to the 
desirable substrate specificity and a good understanding of drug characterization, the 
mephenytoin method was well accepted as a golden standard. The utility is, however, 
somewhat limited due to its low availability in markets [35]. 
Omeprazole has been intensively evaluated as a probe for CYP2C19 phenotyping 
including the work as part of this thesis. The Metabolic Ratio (MR) between 
omeprazole and 5-hydroxyomeprazole was validated by comparing to mephenytoin S/R 
ratio. The assay was widely adopted by users to identify the EMs and PMs in their 
studies [36]. As one of the five probes, omeprazole was selected in the Karolinska 
cocktail for phenotyping the five human CYP450 enzymes [37]. FDA now also 
recommends omeprazole to be used for evaluation of CYP2C19 metabolism both in 
vitro and in vivo. Other efforts towards phenotyping CYP2C19, such as using clobazam 
or lansoprazole, are also reported [38]. 
It is generally believed that phenotype expresses the current activity of the particular 
enzyme when the test is performed, and also reflects precise information about an 
individual’s metabolism. Unlike inherited characteristics, the phenotype determined 
under certain circumstance may vary for the same individual as CYP450s are 
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susceptible to variability through induction and inhibition. A strong inhibitor or liver 
diseases could transfer an EM to a PM category [39], [40].  
1.3.3 Interindividual variability  
Polymorphism of drug metabolism enzymes is one of the major causes of high 
interindividual variability in the PK of CYP2C19 substrates. The variability often leads 
to marked differences in extent of metabolism, drug concentration-time profile or drug 
exposure and, consequently, pharmacological effect or toxicity.  
The clinical impact of CYP2C19 polymorphism is well documented [41], [42], [43]. The 
best example on drug metabolism is the case of omeprazole [44]. The formation of 
hydroxyomeprazole is primarily mediated by CYP2C19 and polymorphic CYP2C19 
activity has significant impact on the PK of omeprazole. When a single dose of 20 mg 
omeprazole was given to a group of EMs, IMs, and PMs, plasma concentrations of 
omeprazole differed remarkably among these three phenotypes in Japanese subjects. The 
relative AUC (area under curve) values in EMs, IMs, and PMs were 1:3.3:12.1 
(421:1402:5108 ng•h/mL) [44]. A similar result was also observed with esomeprazole, 
the (S)-isomer of omeprazole [45]. For other PPIs, the exposure to lansoprazole or 
pantoprazole was found to be approximately 5-fold higher in PMs than in EMs of 
CYP2C19 [46].  
Further influence on PK of PPIs is expected when coadministration of other drugs which 
are inhibitors or inducers of CYP2C19 are administered. Oral contraceptives (OCs) have 
been shown to inhibit the formation of hydroxyomeprazole, leading to more than 2-fold 
reduction of CYP2C19 activity in healthy EM subjects [47]. In PMs, the CYP3A4 
mediated metabolic pathway of omeprazole to omeprazole sulphone became dominant 
due to impaired CYP2C19 metabolism. It is conceivable that inhibition of CYP3A4 in 
PMs could significantly change the PK of PPIs. Ketoconazole (200 mg/day), a strong 
inhibitor of CYP3A4, doubled the inhibition of omeprazole sulphone formation in PMs 
compared to EMs. For parent drug, the AUC of omeprazole increased 1.4-fold and 1.9-
fold in EMs and PMs, respectively, after coadministration of ketoconazole [48]. 
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1.3.4 Interethnic variability 
The frequency of CYP2C19 polymorphism shows marked interethnic differences. 
Numerous studies have been performed to determine the phenotype trait and frequency of 
PMs in various populations. 
The distribution of PMs in selected ethnic groups is summarized in table 1. As 
presented, the frequency of CYP2C19 PMs is relatively high in Japanese [49], Chinese 
and Koreans [50], but low in Caucasians, Africans [51], [52] and Arab populations [53]. 
The presence of PMs were too low to be detected in Cuna Indians of Panama [54] 
whereas 79% of the population is PM on the island of Vanuatu in the Pacific Ocean 
[55], [56]. CYP2C19*2, *3 and their frequency, presented in Table 1, will be discussed 
in section 1.4. 
Table 1. Distribution of PM and allele frequency of CYP2C19*2 and *3 in selected 
ethnic groups  
Ethnic group n 
Allele frequency 
PM% Reference 
*2 *3 
Caucasian      
Danish 358, 239 0.038 0 2.5 [57], [58] 
Dutch 765, 4301 0.133 0.002 1.8 [59] 
Italian 360 0.111 0 n.a. [60] 
Russian 290 0.114 0.003 2.3 [61] 
Swedish 488, 253 0.15 0 3.3, 2.8 [62], [63] 
African      
Ethiopian 114 0.136 0.018 5.3 [52] 
Nigerian 92 n.a. n.a. 4.3 [64] 
Tanzanian 216, 251 0.10-0.179 0-0.03 4.6 [65], [66] 
Zimbabwean 103 0.131 0 3.9 [67] 
Middle East      
Saudi Arabian 97 0.15 0 2.1 [68] 
Jewish Israeli 140 0.15 0.01 2.9 [53] 
Indian and East 
Asians      
Indian (south, north) 341, 121 0.35, 0.30 0.01, 0 20.8 [69], [70]  
Chinese (Han, Bai, 
Dai,Taiwanese) 
101, 202,193, 
118 0.26-0.37 0.034-0.075 13.4-19.8 [71], [72], [68] 
Japanese 53, 140 0.23-0.35 0.104-0.11 15.1 [73] 
Korean 103 0.21 0.012 12.6 [50] 
Oceanian      
Faroese 312 0.029 0 0 [74] 
Vanuatu 100, 5538 0.57, 0.633 0.25, 0.144 79 [56], [55] 
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1.4 GENETIC POLYMORPHISM OF CYP2C19 
The CYP2C19 enzyme is encoded by the CYP2C19 gene, which is located on 
chromosome 10q24 along with the other CYP2C genes in the order of CYP2C18- 
CYP2C19-CYP2C9-CYP2C8 from centromere to telomer [7]. All members of the 
CYP2C sub-family exhibit genetic polymorphism.  
Genetic variations in CYP2C19 and molecular mechanism have been intensively 
studied using different methodologies with various materials. An initial study was 
performed in liver biopsy specimens from EMs and PMs, suggesting a deficiency of a 
specific CYP450 isozyme [75], [76]. Numerous efforts followed in several laboratories, 
including purification of proteins [77], [78], identification by antibodies [79], and 
expression of a CYP2C19 cDNA in yeast [30]. After tedious work with the highly 
homologous CYP2C8, CYP2C9, and CYP2C19 genes, de Morais et al identified the 
first allele mutation and designated it CYP2C19m1 (i.e. CYP2C19*2) [80], with reverse 
transcription and amplification of mRNA from liver samples. The second mutation was 
found in a DNA sample of a Japanese PM subject, defined as CYP2C19m2 at the time 
(i.e. CYP2C19*3) [81]. When specifically searching for variants that could explain the 
large variability in enzyme activity within the EM phenotype and why some have such 
high activity, Sim and coworkers at Karolinska Institutet found a common novel 
CYP2C19 gene variant (CYP2C19*17) [82] that provides increased CYP2C19 activity 
by enhancing CYP2C19 expression.  
1.4.1 Clinically relevant allele variants 
To date, at least 34 allele mutants of CYP2C19 have been documented at 
http://www.cypalleles.ki.se [83], an online CYP-allele database widely used around the 
world. Although most of the mutants are rare and functionally silent, the alleles 
CYP2C19*2-*8 lead to either loss-of-function or reduced enzyme activity, explaining 
almost all PMs of CYP2C19. On the other hand, CYP2C19*17 is associated with 
increased CYP2C19 activity and is also known as the “gain-of-function” allele. The 
wild-type CYP2C19 allele, producing a normal function of CYP2C19 enzyme activity, 
is designated as CYP2C19*1. Table 2 lists dbSNP and main changes in cDNA and 
genes for the most common alleles that have clinical relevance. 
 
12 
Table 2* The common CYP2C19 polymorphisms structure and sites of change 
Allele 
Nucleotide changes 
dbSNP Trivial name 
Enzyme 
activity cDNA Gene 
CYP2C19*1     Normal 
CYP2C19*2 681G>A 19154G>A rs4244285 m1 None 
CYP2C19*3 636G>A 17948G>A rs4986893 m2 None 
CYP2C19*4 1A>G 1A>G rs28399504 m3 None 
CYP2C19*5 1297C>T 90033C>T rs56337013 m4 None 
CYP2C19*6 395G>A 19294T>A rs72552267 m5 None 
CYP2C19*7  12748G>A rs72558186  None 
CYP2C19*8 358T>C 12711T>C rs41291556  Reduced 
CYP2C19*17  –806C>T rs12248560  Increased 
*based on http://www.cypalleles.ki.se [83]  
CYP2C19*2 variant is the result of a single base pair alteration G> A at base 681 
located in exon 5, producing a premature stop codon 20 amino acids downstream. This 
change results in a truncated non-functional protein product [80]. 
CYP2C19*3 gene has a mutation 636G>A in exon 4, creating a premature stop codon 
and producing a truncated inactive enzyme [81]. 
CYP2C19*4 is a mutation of A>G at the first base of exon 1. This change alters the 
initiation codon, producing no protein product [84]. 
CYP2C19*5 is characterized by 1297C>T mutation in exon 9, leading to amino acid 
substitution Arg433Trp and markedly reducing enzyme activity [85]. 
CYP2C19*6 has a mutation 395G>A in exon 3, leading to amino acid substitution 
Arg132Gln and affecting structure and stability. This change results in an inactive 
enzyme [86]. 
CYP2C19*7 mutation is a result of T>A inversion at 5’-splice site, creating intron 5 
splicing defect and affecting protein syntheses [87]. 
CYP2C19*8 is characterized by 358T>C mutation in exon 3, leading to amino acid 
substitution Trp120Arg and subsequently producing reduced enzyme activity [87]. 
CYP2C19*17 gene has 2 linked mutations, -806C>T and -3402C>T with high linkage 
in the 5’-regulatory region, leading to increased expression and activity [82].  
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1.4.2 CYP2C19 genotyping and allele frequency  
Although genomic DNA can be prepared from other sources, preparation of DNA from 
peripheral blood has been used in many studies for CYP2C19 genotyping. PCR-based 
tests for the two most frequent loss-of-function alleles (CYP2C19*2 and CYP2C19*3) 
were available soon after the mutations were reported. Attributing to the new 
technology applied in genomics, CYP genotyping has become robust, high-throughput 
and commercialized with standard procedures of validation and quality control (QC).  
The frequency of CYP2C19*2 allele was as presented in Table 1: 0.038-0.15 in 
Caucasians [88], [61], [89], [90], [91], [92], 0.21-0.37 in Indians and East Asians [50], 
[68], [69], [70], [71], [72], and 0.10-0.18 in Africans [51], [66], [67], [93]. The highest 
(0.57-0.63) and lowest (0.029) prevalence of the CYP2C19*2 allele have been reported 
respectively from the island populations of Vanuatu [56] and Faroese [74]. With respect 
to CYP2C19*3 allele, Vanuatu also showed the highest (0.144-0.25) frequency, 
following by Korean (0.12) [50] and Japanese (0.104-0.11) population [73], [94]. All 
Caucasians and Africans have the frequency of CYP2C19*3 less than 0.007 (0.7%) 
except for Ethiopians who have a frequency of 0.02 (2%) [52]. For additional null 
alleles (CYP2C19*4-*8), the inter-ethnic distributions are not available, perhaps due to 
extremely low incidence of each allele.  
The higher frequency of mutant alleles, the larger portion of heterozygotes based on the 
Hardy-Weinberg equation. For enzyme activity, homozygous carriers (two identical 
copies) of functional CYP2C19 genes differ from heterozygous carriers (one copy), 
following the gene-dose-effect pattern. For example, heterozygous for CYP2C19*2 or *3 
(i.e. CYP2C19*1/*2 or CYP2C19*1/*3 genotype, also known as heterozygous EM) is 
associated with lower enzyme activity as compared to carriers of *1/*1 (homozygous 
EM). In Asians, the portion of heterozygous EMs is about twice as high as in Caucasians. 
A higher AUC of omeprazole was seen in Chinese EMs (2.6 μM•h) than Caucasian EMs 
(0.9 μM•h) with comparable AUCs in PMs (13.3 in Chinese vs. 11.1 in Caucasians), 
reflecting that Chinese EMs have lower CYP2C19 activity [95]. The higher portion of 
heterozygous EMs in Chinese is also likely the main reason to explain the slower 
clearance of diazepam in this population compared to Caucasians [96]. 
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The frequency of CYP2C19*17 allele was reported to be 0.18 in Caucasians and 0.04 in 
Asians. This gain-of-function allele is, however, less studied in other ethnic groups 
compared to the loss-of-function alleles because it was undiscovered until 2006 [82]. 
1.4.3 Nongenetic host factors influencing CYP2C19 expression and function 
There are still high inter-individual and inter-ethnic differences in the metabolism of 
CYP2C19 substrates within homozygous carriers of CYP2C19*1. Heritable genetic 
variation cannot explain all differences affecting CYP2C19 expression and function. As 
reported in some studies [97], [98], age contributes to reduction of drug clearances and 
long half-life. The capability of drug metabolism appears substantially lower (29-45%) 
in the elderly population (70-100 years) compared with the young control group (20-50 
years) [99]. However, no significant differences are found in CYP enzyme activity 
between young and old populations [100]. It is generally believed that decline of liver 
blood flow and liver volume with age in humans is part of reasons responsible for the 
diminished clearance of drugs in elderly population. The effect of gender on the activity 
of CYP2C19 is controversial. Both higher or lower activity in females than males have 
been reported [94], [101]. Generally, sex affects PK through body weight, fat 
distribution, liver blood flow, and expression of enzymes and transporters, but no 
gender bias was found in the expression of CYP2C19 in a gene expression profiling 
study where 40 ADME-related genes were screened in 112 male and 112 female livers 
[102]. Oral contraceptives (OC) are proven to be moderate inhibitors of CYP2C19 [47]. 
As OC are often not considered as an exclusionary criterion in clinical trials, the PK 
results can be confounding for the women with child-bearing potential who take OCs 
regularly.  
Disease states also influence enzyme activity. For CYP2C19, it has been documented to 
be moderately reduced in liver disease [103], [104]. This is perhaps in part due to one or 
more of the following reasons: 1) reduction of liver blood flow; 2) loss of functional 
hepatocytes; 3) alternation of the architecture of the liver; and 4) lower synthesis of 
serum proteins.  
Epigenetic factors also potentially influence CYP2C19 metabolism, for example 
miRNAs regulating gene expression. Of special interest for pharmacogenetic aspects 
are SNPs in miRNAs and miRNAs binding site as well as miRNAs copy number 
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variations [105]. Although there are no direct examples showing an impact of miRNAs 
on CYP2C19, the results of CYP2C8 being regulated post-transcriptionally by miR-103 
and miR-107 [106] demonstrates an influence of miRNAs on ADME regulation and 
potential relevance in drug response. 
1.5 CLINICAL IMPACT OF CYP2C19 POLYMORPHISM 
Individuals vary greatly in their response to drug therapy. After receiving a standard dose 
of a drug that is recommended based on a population average, some patients could have 
insufficient response, whereas others may experience adverse effects. Because CYP2C19 
plays an important role in metabolizing several widely prescribed drugs, such as 
omeprazole, citalopram, and clopidogrel, the clinical relevance of genetic polymorphism 
to the efficacy and safety of drugs has received a lot of attention. Although all drugs 
metabolized by CYP2C19 are likely to show clinical importance on genetic 
polymorphism, the drugs for which CYP2C19 is the primary metabolic pathway and 
those with narrow therapeutic ranges are particularly susceptible.  
1.5.1 Variability in drug response  
Both PK and PD determine intensity and duration of a pharmacologic agent. After a drug 
is administered, it will undergo ADME/ PK processes while interacting with the PD 
target. For drugs that are CYP2C19 substrates, the enzyme polymorphism is deemed to 
be one of the independent determinants among a number of factors that contribute to the 
inter-individual variability. 
The influence of CYP2C19 polymorphism on omeprazole PK has been discussed in 
section 1.3.3 discussing interindividual variability. The effect of CYP2C19 
polymorphism on PD is also primarily studied with omeprazole. Furuta et al investigated 
intragastric pH in 16 healthy subjects following administration of omeprazole [44]. 
Significant differences were observed among the three phenotype groups, and the mean 
values of 24-hr intragastric pH in EMs, IMs, and PMs were 2.1, 3.3 and 4.5, respectively. 
The first study in this thesis also demonstrated that omeprazole increases plasma gastrin 
more in PMs than that in IMs or EMs, and the level of increase is correlated with the 
plasma AUC of omeprazole. In addition to the intragastric pH and plasma gastrin, several 
other PD parameters including pepsinogen I, plasma chromogranin A, and oxyntic 
16 
mucosa were reported to be affected in a manner consistent with CYP2C19 
polymorphism [107], [108]. 
Clopidogrel is a clinically important cardiovascular drug that requires oxidation to form 
its active thiol metabolite. As presented in Figure 2, CYP2C19 participates in every step 
of activation among multiple CYP enzymes, so its role in the conversion of clopidogrel is 
clearly demonstrated. 
clopidogrel
2-oxo-clopidogrel
CYP1A2
CYP2B6
CYP2C19
Esterases Inactive metabolites 
(85% of clopidogrel dose)
CYP2B6
CYP1A2
CYP2C19
CYP3A4
Active 
metabolite
 
Figure 2 Structure of clopidogrel, metabolites, and metabolic pathways  
There is large inter-individual variability in clopidogrel response. Depending on the 
criteria used, approximately 15-40% are considered non-responders with high residual 
platelet aggregation [109], i.e. “clopidogrel-resistant”. Genetic variation in the CYP2C19 
gene leads to significant differences in exposure to the active metabolite, and 
subsequently translates the change into clinically meaningful impact on cardiovascular 
events (e.g., death, stent thrombosis, myocardial infarction, and stroke) up to one year 
follow-up periods. For CYP2C19 poor metabolisers, high residual platelet reactivity with 
a 3-fold increase in one year incidence of death and myocardial infarction has been 
observed [110]. These findings of CYP2C19 PMs with significantly lower anti-
coagulation effect of clopidogrel and higher risk of major adverse cardiovascular events 
are supported by a number of clinical studies [111], [112], [113], [114], [115]. In 2009 
and 2010, FDA modified the label of Plavix (clopidogrel) by adding warnings in its 
package insert. The agency also alerted patients and clinicians [116] that the drug can be 
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less effective in people who have reduced CYP2C19 function, for example PMs. In order 
to manage the risk, FDA also recommends CYP2C19 genotyping be considered prior to 
prescribing the drug. 
1.5.2 Application of pharmacogenetics and personalized medicine 
As discussed in clopidogrel case, public interest in pharmacogenetics has increased 
specifically during the human genome project and since its completion on 4/4/2013. The 
terms of “pharmacogenomics”, “pharmacogenetics”, “genomic biomarker”, and 
“personalized medicine” often appeared in reports/publications with slightly different 
definitions. To setup a scope of discussion, the terms used in this thesis are defined as 
follows:  
• Pharmacogenomics - The study of variations of DNA and RNA characteristics as 
related to drug response 
• Pharmacogenetics - The study of variation in DNA sequence as related to drug 
response. 
• Genomic biomarker - a measurable DNA and/or RNA characteristic that is an 
indicator of a normal biological or a pathogenic process and/or a response to 
therapeutic or other interventions 
• Personalized medicine -The application of genomic and molecular data to 
improve the delivery of healthcare, facilitate the discovery and clinical testing of 
new products, and help determine individual predisposition to a particular disease 
or condition. 
The first three definitions are adapted from Note for Guidance on Definitions for 
Genomic Biomarker, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample 
Categories (EMEA/CCHMP/ICH/437986/ 2006) and the last one is adapted from the US 
Genomics and Personalized Medicines Act 2007.  
The information generated from genotyping/phenotyping tests can be tailored to guide 
drug choice and/or dosage regimen for an individual patient. Pharmacogenetics-guided 
warfarin dosing algorithms provide an example of personalized medicine using 
demographic, clinical, and genetic factors. Warfarin is known to have more than a 10-fold 
individual variation in dosage requirement. Genetic polymorphism of the 
pharmacological target gene (VKOR) and metabolism gene (CYP2C9 encode enzyme 
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CYP2C9 for metabolizing S- warfarin) contribute to the large interindividual variability 
of warfarin. Together with age and bodyweight, variation in genes account for more than 
50% of variance in dosage requirement. Unlike the standard practice of “one-dose-fits-
all”, a number of algorithms by incorporating genetic, clinical factors, age and body size 
have been proposed for maintenance dosing of warfarin [117], [118], [119]. Using 
internet-based clinical trial protocols [120], the Swedish WARG study (The Warfarin 
Genetics) had a large sample size adequately powered to test smaller effects among 29 
candidate genes. In 1496 Swedish patients who started warfarin treatment, 183 
polymorphisms in the 29 genes were genotyped [121], and 59% of the variance in 
warfarin dosing could be explained by CYP2C9, VKORC1, age, sex and drug interactions. 
The approach of personalized medicine is not always as smooth as expected. We 
discussed the cases of clopidogrel in Section 1.5.1 where the clinical utility of genotyping 
was clearly demonstrated in a number of studies including a large trial [111] consisting of 
162 healthy subjects and 1477 patients. This TRITON-TIMI study published in New 
England Journal of Medicine, revealing 53% relative increase in the risk of death from 
cardiovascular causes or stroke for carriers of at least one loss-of-function allele of 
CYP2C19 as compared with non-carriers. However, a number of studies, including two 
meta-analyses [122], [123], have recently concluded that the predictive value of 
pharmacogenetic testing prior to clopidogrel treatment is limited. The results deviated 
largely from FDA’s recommendations. The American Heart Association and American 
College of Cardiologists also challenge whether the evidence is sufficient to support the 
genotype-guided prescription paradigm.  
1.6 CYP2C19 SUBSTRATES 
The following are the typical CYP2C19 substrates related to this thesis: 
1.6.1 Omeprazole  
Omeprazole was the first proton pump inhibitor in clinical practice. It effectively 
suppresses gastric acid secretion and is widely used to treat acid-related disease [124]. 
The drug acts by irreversible binding to the H+-K+ ATPase in the parietal cell [125] and 
the anti-secretory effect is related to the area under the plasma concentration-time curve 
(AUC) of omeprazole. PK of omeprazole has been well documented in both healthy and 
duodenal ulcer patients [126], [127]. With respect to elimination, omeprazole is nearly 
completely metabolized in the liver, mainly by CYP450 enzymes. As presented in Figure 
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3, CYP2C19 is responsible for the metabolism of omeprazole to 5-hydroxyomeprazole 
and omeprazole sulphone to 5-hydroxyomeprazole sulphone while CYP3A4 is involved 
in the sulphoxidation pathways.  
omeprazole
carboxyomeprazole
hydroxyomeprazole hydroxy sulphone omeprazole sulphone
CYP2C19 CYP3A4
CYP3A4 CYP2C19
 
Figure 3 Structure of omeprazole and metabolites 
Kinetic parameters for omeprazole to 5-hydroxylation activities were determined by 
recombinant CYP2C19 in insect microsomes. The low Km and high Vmax values 
generated from in vitro methods indicated that omeprazole is an efficient substrate for 
CYP2C19 [128]. Moreover, the role of CYP2C19 enzyme in the metabolism of 
omeprazole has been well characterized in a number of clinical studies including healthy 
subjects and patients. Based on the robust enzyme-substrate characterizations, 
omeprazole was further selected as a probe drug in clinical evaluation to help understand 
the nature and magnitude of DDIs where CYP2C19 may be involved [4], [37]. 
1.6.2 Citalopram/escitalopram 
Citalopram and escitalopram are selective inhibitors of serotonin reuptake (SSRI) 
widely used for the treatment of depression and anxiety disorders [129]. Escitalopram is 
the S-enantiomer of racemic citalopram and binds with high affinity to the human 
serotonin transporter [130]. Overall, approximately 85% of the drug(s) is eliminated by 
the liver and the rest by the kidney. CYP2C19 is the major enzyme in the liver 
catalyzing the metabolism of citalopram followed by CYP3A4 and CYP2D6 to a lesser 
extent [131] (Fig 4). The role of CYP2C19 in N-demethylation of citalopram was 
demonstrated in cDNA expressed human cytochrome. The metabolite 
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desmethylcitalopram (DCT) is significantly less active and its contribution to the 
overall action of citalopram is negligible. Compared to young and healthy subjects, the 
elderly and patients with hepatic or renal failure have slower elimination processes. 
Potent inhibitors of CYP2C19 and 3A4 might decrease citalopram clearance [132]. 
citalopram DCT
CYP2C19
CYP2D6
CYP3A4
 
Figure 4 Structure of citalopram and its demethylation metabolite (DCT) 
 
Since CYP2C19*2 and CYP2C19*3 account for the majority of loss of function alleles 
associated with the PM phenotype, several studies have investigated the effect of 
CYP2C19*2 and CYP2C19*3 on citalopram exposure and its clinical implications. For 
CYP2C19*17, a few studies have been conducted to examine the impact of this gain-of-
function allele on steady state citalopram concentrations and clinical outcomes [133], 
[134], [135].  
The pharmacogenetic studies of citalopram have yielded somewhat inconsistent results, 
especially with regard to the quantitative impact of the CYP2C19*17 allele. Most 
studies were not powered to provide useful quantitative estimates of the genotype 
effect. From a PD standpoint, fewer than 50% of patients treated with SSRI including 
citalopram experience a complete remission of their symptoms [136]. Among a number 
of factors contributing to the low response rate, insufficient drug exposure is deemed to 
be one of the reasons.  
1.6.3 Warfarin  
Warfarin is an oral anticoagulant, commonly described as vitamin K antagonist and used 
for the treatment and prevention of thromboembolic disorders [117]. Its anticoagulant 
effect is mediated via inhibition of the enzyme vitamin K epoxide reductase (VKOR) 
[137]. Due to a narrow therapeutic index and large interindividual variability in dose 
requirement, the clinical use of warfarin is challenging. The effectiveness and safety of 
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warfarin is dependent on administering an individually titrated dose to maintain 
prothrombin time, expressed as the international normalized ratio (INR or PT-INR) 
within a therapeutic range of 2.0-3.0.  
Warfarin is administered as a racemic (1:1) mixture of its S- and R-enantiomers. Both the 
PK and PD of S- and R-warfarin differ. S-warfarin is considered to be 3-5 times more 
potent than R-warfarin as an inhibitor of VKOR. S-warfarin is almost exclusively 
metabolized by the cytochrome P450 CYP2C9 [138]. The metabolism of R-warfarin, on 
the other hand, is catalyzed by multiple CYP enzymes including CYP2C19, CYP3A4, 
CYP1A2, and possibly CYP2C8 (Fig 5), as assessed in vitro using recombinant 
CYP2C19, human liver microsomes and chemical inhibitors by Kim So-Young et al 
[139].  
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Figure 5 Structure of S-, R-warfarin and metabolic pathways 
CYP2C9 polymorphisms have been well documented as a major determinant on S- (but 
not R-) warfarin clearance, and on warfarin dose requirement. Compared to S-warfarin, 
the PK and PD of R-warfarin are much less studied. In a single dose study in Japanese 
healthy volunteers, an approximately 30% higher AUC of R-warfarin was demonstrated 
in CYP2C19 poor metabolisers compared to extensive metabolisers [140]. None of the 
studies published so far have addressed the potential impact of the CYP2C19*17 allele, 
associated with increased CYP2C19 activity and contributing to variability in enzyme 
activity within the extensive metaboliser group, on warfarin clearance and dose 
requirement.  
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2 AIM 
The overall aim of this thesis was to investigate the influence of CYP2C19 
polymorphisms on PK and PD of clinically important CYP2C19 substrates, to quantify 
the effect of functional CYP2C19 allele variants including the gain-of-function allele 
(CYP2C19*17) on drug exposure and response, to advance knowledge and 
understanding of inter-individual variability in drug therapy. The specific aims of the 
individual studies were the following: 
 
Study I: To investigate the disposition of omeprazole and its effect on plasma gastrin 
levels after single and multiple oral doses in the three phenotype groups (PMs, IMs, and 
EMs) of S-mephenytoin hydroxylation. 
  
Study II: To investigate the distribution of the ratio between the 3-hour plasma 
concentrations of omeprazole and hydroxyomeprazole (i.e. metabolic ratio, MR) in a 
large healthy Swedish population and to assess the correlation between the MR of 
omeprazole and the S/R ratio of mephenytoin as well as the CYP2C19 genotype. 
 
Study III: To assess the potential for pharmacokinetic interactions between 
carbamazepine (CBZ) and omeprazole and to study the inducibility of CYP3A4 and 
CYP2C19 by CBZ, using omeprazole as a probe for these two enzyme activities. 
 
Study IV: To assess the potential influence of CYP2C19*17 on R-warfarin clearance, and 
the combined effect of CYP2C19, CYP2C9 and VKORC1 polymorphisms together with 
non-genetic factors on warfarin dose and INR response. The S/R ratio of warfarin in 
relation to VKORC1 genotype was also investigated. 
  
Study V: To quantify the effect of functional CYP2C19 allele variants on 
citalopram/escitalopram exposure by means of systematic review and meta-analysis. 
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3 METHODS  
3.1 SUBJECTS 
Interphenotype study (I) 
Fourteen (14) previously phenotyped healthy Swedish volunteers were selected and 
divided into three groups with respect to the S/R ratio of mephenytoin. Five (4 males and 
1 female) with an S/R ratio close to 1 (0.91-1.10) were PM. Another 5 subjects (4 males 
and 1 female) were rapidEM with an S/R ratio < 0.05. The remaining 4 (3 males and 1 
female) volunteers had an S/R ratio range between 0.27 and 0.75, and were classified as 
heterozygous EM (hetEM) because each of them has a PM parent. All subjects were 
between 23 and 33 years of age. 
Population study (II) 
One hundred and sixty (160) healthy Swedish Caucasian subjects (72 males and 88 
females) were recruited. The subjects were between 19 and 54 years old. Most were from 
the staff of the Huddinge Hospital, medical students at Karolinska Institute, and their 
friends. Subjects who had no drugs, except for oral contraceptives, one week before or 
during the study were eligible to the study. 
Carbamazepine study (III) 
Five Swedish subjects (4 females and 1 male) with newly diagnosed epilepsy requiring 
long term treatment of carbamazepine participated. The patients were between 23 to 66 
years of age.  
Warfarin study (IV) 
This study included 150 (99 males and 51 females) Italian outpatients from two 
previously published clinical studies. The patients were between 22 to 87 years old and 
all were on stable maintenance doses of warfarin titrated to a target INR value between 
2.0 and 3.0. 
Meta-analysis study (V) 
The studies where subjects received at least one single oral dose of citalopram or 
escitalopram and had been either phenotyped or genotyped with at least two CYP2C19 
alleles (*1, *2, *3, *17) were included. All reports deemed eligible for inclusion were 
retrieved in full-text and the relevant data were re-extracted independently. No 
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restrictions were applied to subject characteristics, treatment duration, or concomitant 
drugs. A total of 987 subjects from 16 studies were included of which 39.6% were men. 
The age of the participants ranged from 15 to 84 years. 
All clinical trials were approved by the Regional Ethical Review Board (or Committee). 
All studied were performed according to ICH-GCP guidelines, the declaration of 
Helsinki, and applicable local legislation. 
 
3.2 ANALYTICAL METHOD 
3.2.1 Genotyping 
Population study (II) 
DNA was isolated from peripheral leukocytes using a guanidinium isothiocyanate 
method. The defective CYP2C19m1 allele was identified by PCR amplification of DNA 
with use of specific primers as described by de Morais et al [81]. After 35 cycles, the 
PCR products were digested with Sam I restriction enzyme overnight. Both the PCR 
products before and after digestion were analyzed on 3% agarose gels stained with 
ethidium bromide to determine the genotype of CYP2C19 for CYP2C19*2.  
Warfarin study (IV) 
DNA was extracted from peripheral leukocytes using the Qiagen Cell Culture DNA kit. 
Five single nucleotide polymorphisms (SNPs) were genotyped using validated TaqMan 
genotyping assays from Applied Biosystems (for rs12248560C>T, CYP2C19*17; for 
rs4986893G>A, CYP2C19*3; for rs28399504A>G, CYP2C19*4; for rs10509681A>G, 
CYP2C8*3; for rs992323G>A, VKORC1*2). The analyses were carried out using an 
ABI PRISM 7500 Real-Time PCR System or an Applied Biosystems StepOnePlus 
Real-Time PCR system. The genotypes of CYP2C19*2, CYP2C9*2 and CYP2C9*3 
were available since before as described [141]. 
 
3.2.2 Drug Analysis  
3.2.2.1 Omeprazole and its metabolites 
A liquid chromatography method was employed to quantify plasma concentration of 
omeprazole, hydroxyomeprazole, and omeprazole sulphone in Studies I, II, and III by 
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the HPLC method of Lagerström et al with modification [142]. Standard curves in the 
range of 0-500 nM were prepared on each day of analysis. The intra-day and inter-day 
variation (CV) for omeprazole and its metabolites were <10%.  
3.2.2.2 Carbamazepine and its metabolites 
Plasma concentration of carbamazepine and its 10, 11-epoxide metabolites were 
determined in Study III by HPLC according to a method developed by Tomson et al 
[143]. 
3.2.2.3 S-warfarin and R-warfarin  
S-warfarin and R-warfarin plasma concentrations were determined in Study IV by an 
HPLC method developed by Henne et al [144] with modifications described by Scordo et 
al [141]. 
3.2.3 Gastrin 
Plasma gastrin levels were analyzed in Study I by radioimmunoassay according to 
Nilsson [145] using antibody 4562 (generously supplied by Professor Jens Rehfeld, 
Denmark) and synthetic human gastrin I (Milab, Malmö, Sweden) as a tracer. 
3.3 DATA ANALYSIS AND STATISTICAL METHOD 
PK parameters were calculated using non-compartmental analysis (NCA) technique. 
Cmax was noted as the maximum concentration measured during the dosage interval. 
The area under the plasma concentration versus time curve (AUC) was estimated using 
the trapezoidal rule. The plasma elimination half-life (T1/2) was obtained by least 
squares linear regression analysis of the terminal log plasma concentration vs. time 
curves. Assuming complete absorption of the drug in the gastrointestinal tract, the oral 
plasma clearance (CLo) was calculated by dividing the given dose by AUC.  
Statistical software programs were employed to calculate significance of differences and 
correlations as described in the respective paper. PK parameters were log-transformed to 
reduce non-normality. Descriptive statistics included calculation of median and 
interquartile range or total range. 
Methods for between-group comparison included the Mann-Whitney U-test (papers I, 
II, IV), unpaired Student’s test (paper I), paired Student’s test (paper III), and analysis 
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of variance (ANOVA) (paper IV) for continuous variables, and Pearson's Chi-square 
test (paper IV) for categorical variable. When the overall test showed a significant 
difference among the groups, Bonferroni test was used as post hoc analysis to elucidate 
the difference between individual groups (paper IV). 
Regression analysis was performed by Spearman’s rank correlation in the relations 
between mephenytoin S/R ratio and ratio of omeprazole over hydroxyomeprazole 
(papers I and II), and the relation between AUC of omeprazole and that of gastrin 
(paper I). Multivariate linear regression was used to assess the influence of continuous 
or categorical predictors on continuous outcome (paper IV), and the adjusted value of 
R2 was a measure of the portion of variance.  
Pooled effect estimates were calculated by means of fixed effect and random effects 
meta-analyses from several studies in paper V. The individual studies were weighted 
according to inverse variance. The Cochran’s Q test and the percentage of total 
variability across studies (I2) were used to assess heterogeneity among studies. Potential 
sources of heterogeneity and bias from small study effects were analyzed by a 
univariate linear regression and funnel plots, respectively. 
All tests were two-tailed, and p-values <0.05 were considered to be statistically 
significant. 
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4 RESULTS  
4.1 PAPER I 
4.1.1 Study design 
Fourteen subjects were assigned to the groups of PM (N=5), rapidEM (N=5), and hetEM 
(N=4) based on the S/R ratio of mephenytoin. Omeprazole 20 mg was administered orally 
once daily for 8 days. Blood samples were drawn at predose and selected hours post dose. 
Omeprazole, hydroxyomeprazole, omeprazole sulphone and gastrin levels were 
determined. The PK parameters (Cmax, AUCs, CLo, andT1/2) were derived.  
4.1.2 Results 
When 20 mg of omeprazole was given orally for 8 days, plasma concentrations differed 
markedly among the three different CYP2C19 phenotypes; rapidEMs (or EMs), hetEMs (or 
IMs) and PMs. The mean AUC values of omeprazole were 1130, 5984 and 14820 nM•h for 
EMs, IMs and PMs, respectively, with a relative ratio of 1:5.3:13.1 (Fig 6). Significant 
differences in the plasma gastrin levels (used as a PD marker in the study) were also observed 
among the three phenotype groups following the 8th dose. The mean AUC(0-10h) values of 
gastrin were 246, 555 and 621pM•h respectively, for EMs, IMs and PMs of CYP2C19, while 
the corresponding gastrin AUC values after the 1st dose were 221, 254 and 333 pM•h (Fig 7). 
There was a doubling of the AUC of gastrin after the eighth dose compared with the first 
omeprazole dose in both PM and IM groups.  
 
Figure 6 Left panel: Mean plasma 
concentrations of omeprazole in rapidEM 
(● n=5), hetEM (□ n=4) and PM (■ n=5) 
of S-mephenytoin following the first dose 
of 20 mg omeprazole orally. Right panel: 
as in the left panel, but the mean plasma 
concentrations were measured after the 
eighth dose following administration of 
20 mg omeprazole once daily. 
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Figure 7 a) Mean gastrin levels in the 
three groups following a single 20 mg 
omeprazole dose. There was no 
significant difference between the three 
groups either before or after drug 
administration. b) Mean gastrin levels 
after the eighth dose of omeprazole. 
 
4.2 PAPER II 
4.2.1 Study design 
One hundred and sixty healthy (160) subjects were phenotyped with mephenytoin one 
week or more after omeprazole dosing except for 21 subjects with a known mephenytoin 
phenotype. All subjects received a single 20 mg dose of omeprazole orally. Two blood 
samples were drawn at 3 hours post dose: one for omeprazole and hydroxyomeprazole 
quantification, and another for analysis of CYP2C19*2. The ratio of omeprazole to 
hydroxyomeprazole was calculated.  
4.2.2 Results 
A significant correlation was found between the metabolic ratio (MR) of omeprazole and 
the S/R mephenytoin ratio. The MR of omeprazole varied between 0.10 and 23.8 among 
the 160 subjects. Homozygous carriers of CYP2C19*1 allele had lower MRs of 
omeprazole and S/R ratios of mephenytoin relative to heterozygous and homozygous 
carriers of CYP2C19*2 allele. A good agreement was obtained between genotype and 
phenotype using either omeprazole or mephenytoin as a probe. 
As presented in Fig 8, log MR of omeprazole (left panel) among EMs (wt/wt) was fairly 
normally distributed as compared to S/R ratio of mephenytoin (right panel) where 18% of 
the subjects had an S/R ratio of <0.05. Thereby the omeprazole assay might be capable to 
identify subjects with a very rapid MR of omeprazole or high CYP2C19 activity.  
29 
 
 
 
Figure 8 Frequency distribution of the MR of 
omeprazole (left: n =160) and of the S/R 
mephenytoin ratio (right: n =141). Subjects 
showed as black bars were phenotyped as EM 
using mephenytoin as a probe drug; PMs were 
showed as shaded bars. Within the EM 
phenotype, the genotypes wt/wt and wt/m1 
were different with respect to the 
omeprazole/hydroxyomeprazole ratio (wt/wt, n 
=113; wt/m1, n=40; p=0.0001) and S/R 
mephenytoin ratio (wt/wt, n =99; wt/m1, 
n=35; p=0.0001) using the Mann-Whitney 
test. 
4.3 PAPER III 
4.3.1 Study design 
Five patients requiring long term CBZ treatment were treated twice daily with a daily 
CBZ dose of either 400 mg (n=3) or 600 mg (n=2). Prior to starting CBZ treatment and 
after 3 weeks of CBZ treatment, the patients received a single oral dose of 20 mg 
omeprazole. Blood samples were collected at selected hours after omeprazole intake. 
Omeprazole, hydroxyomeprazole, omeprazole sulphone, CBZ, and the CBZ epoxide 
metabolite were determined. The PK (Cmax and AUC) of omeprazole and its metabolites 
before and during CBZ treatment were calculated. The AUC ratio of 
hydroxyomeprazole/sulphone was used to estimate the relative influence of CBZ 
treatment on the activity of the two CYP isoforms (CYP2C19 and CYP3A4). 
4.3.2 Results 
Both omeprazole and hydroxyomeprazole decreased by approximately 40% in mean 
AUC after coadministration of omeprazole with CBZ while the sulphone metabolite 
increased by 44% (Fig 9). None of the changes were statistically significant. The AUC 
ratios of omeprazole/hydroxyomeprazole were 0.85 and 0.75 with or without 
carbamazepine, suggesting little impact of carbamazepine on CYP2C19 activity. The 
AUC ratios of omeprazole/ omeprazole sulphone were 0.80 and 1.93 (58.5 % reduction, 
p=0.052) with or without carbamazepine intake. A significant decrease (2.58-0.93, 
P=0.046) was observed in the AUC ratios of hydroxyomeprazole/ sulphone metabolites, 
suggesting that the impact of carbamazepine was different on the two CYP isoforms 
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(CYP2C19 and CYP3A4) with more pronounced influence for CYP3A4 than for 
CYP2C19.  
Figure 9 Mean plasma concentrations of a) omeprazole; b) hydroxyomeprazole; and c) omeprazole 
sulphone in 5 patients given a single oral 20 mg dose of omeprazole before (○) and during (●) 
carbamazepine treatment.  
4.4 PAPER IV 
4.4.1 Study design 
This study was based on 150 Italian warfarin-treated patients (on stable maintenance dose 
of warfarin) included in two previously published studies, study A (N=93) [141] and study 
B (N=57) [146]. Plasma samples were taken at steady state (12-14 hours after the last 
dose) for determination of S- and R-warfarin concentrations and INR. The clearances of 
S- and R-warfarin were calculated. All patients were genotyped for CYP2C19*2, *3, *4 
and *17, CYP2C9*2 and *3, CYP2C8*3 and VKORC1*2, of which CYP2C19*2, 
CYP2C9*2 and*3, and partial VKORC1*2 (study B) were available since before. 
4.4.2 Results 
As presented in Fig 10, CYP2C19*17 carriers showed a 1.3-fold higher mean R-warfarin 
clearance (2.5 mL/min) than CYP2C19*2 carriers (1.9 mL/min). Patients with 
CYP2C19*1/*1 genotype had their mean R-warfarin CL in-between the *17 and *2 
carrier groups (2.1 mL/min) and those who carried both CYP2C19*2 and*17 alleles 
displayed a mean CL similar to that of the *17 carriers (2.5 mL/min). The increase in the 
latter 2 groups was not statistically significant. For the influence on INR/daily dose, 
CYP2C19 genotype showed a significant difference (p=0.04) in addition to the CYP2C9 
(p<0.0001) and VKORC1 (p<0.0001) genotypes. The contribution to the variability of 
INR/daily dose was 7%, 36%, and 27% for CYP2C19, VKORC1, and CYP2C9 
genotypes, respectively. Age also explained 7% of the variance.  
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Figure 10. R-warfarin clearance 
categorized by CYP2C19 
genotypes. Log-transformed R-
warfarin clearance with median 
and inter quartile are shown 
graphically and antilog values are 
presented numerically. Bonferroni 
post-hoc test with mean and 95% 
conference interval (CI) was used 
in multiple pairwise comparisons 
on the basis of log-transformed 
values. Statistical significant are 
showed between heterozygous 
and homozygous carriers of 
CYP2C19*2 and CYP2C19*17. 
 
4.5  PAPER V 
4.5.1 Study design 
Systematic review and meta-analysis were preformed to assess the impact of CYP2C19 
genotypes on citalopram/escitalopram exposure with a structured search algorithm and 
eligibility criteria for inclusion. Exposure data from individual studies (N=16) were 
adjusted for between study differences not attributed to CYP2C19 genotype. The 
exposure changes associated with CYP2C19*2, *3, and *17 as compared with 
CYP2C19*1 were pooled in meta-analyses fixed-effect and random-effects models. 
Publication bias and sensitivity analysis were also assessed by funnel plots and meta-
regressions, respectively. 
4.5.2 Results 
Sixteen studies from 14 publications met the inclusion criteria. Eligible studies included 
847 patients from psychiatric patient trials and 140 healthy subjects from 
pharmacokinetic studies. Compared to subjects with EM/EM (CYP2C19*1/*1) 
genotype, the exposure to (es)citalopram increased by 95% (95% CI 40-149%, 
p<0.0001) in the PM/PM (CYP2C19*2/*2, *2/*3/, or *3/*3), 30% (4-55%, p<0.05) in 
the EM/PM (CYP2C19*1/*2 or *1/*3), and 25% (1-49%, p<0.05) in the UM/PM 
(CYP2C19*17/*2 or *17/*3) groups. In contrast, the exposure to (es)citalopram 
decreased by 36% (27-46%, p<0.0001) in the UM/UM (CYP2C19*17/*17) and by 14% 
(1-27%, p<0.05) in the UM/EM (CYP2C19*17/*1) (Fig. 11). 
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Figure 11  The effect of CYP2C19 
genotypes or phenotypes on 
(es)citalopram exposure. The filled 
circles represent the mean change 
(in %) in (es)citalopram exposure 
(using EM/EM as reference) and 
error bars 95% confidence 
intervals of the estimate. The dotted 
line indicates the exposure in the 
reference group (EM/EM). 
Asterisks indicate statistically 
significant differences between 
EM/EM and each of the 5 other 
genotype groups or between 
EMpheno and PMpheno groups, 
*p-value <0.05, ***p value 
<0.0001 
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5 DISCUSSION 
This thesis presents the findings related to CYP2C19 polymorphisms in 5 individual 
studies and also witnessed the progress that has been made over 15 years in the 
understanding of CYP2C19 polymorphism in relation to genetic variants, individual and 
population variability, genotype-phenotype correlation, and the impact on clinical 
practice.  
In Study I, we demonstrated that PMs of S-mephenytoin had significantly slower 
metabolism of omeprazole than IMs and EMs. The metabolic status was associated with 
the S-mephenytoin hydroxylation polymorphism. We identified heterozygous EM from 
family studies and homozygous EM based on a rapid mephenytoin S/R ratio (<0.05). 
Four years late Furuta et al [3] performed a similar study in Japanese but classified 
subjects by genotyping. The results from these two studies were comparable in PMs with 
respect to the mean AUC of omeprazole (14273 vs. 14778 nM•h), suggesting a good 
correlation between phenotyping and genotyping. Our result in EMs, however, was 41% 
lower than Furuta’s, supporting the expectation for the rapid metabolisers with very fast 
mephenytoin S/R ratio of <0.05. More interestingly, the mean AUC of omeprazole in IM 
was also 35% lower in our study than Furuta’s, suggesting a considerable difference 
between Caucasians and Japanese. This ethnic difference is consistent with other studies 
[95], reflecting lower CYP2C19 activity in Asians. 
Study I is the first report, prior to any genotyping method available, demonstrating the 
interphenotype difference of CYP2C19 in pharmacologic effect of omeprazole by means 
of plasma gastrin levels. After multiple doses, the gastrin levels were elevated 
significantly in PM and IM but remained virtually unchanged in EM. The increase of 
gastrin AUC in PM and IM were in an omeprazole-concentration-dependent fashion. This 
finding was in line with Furuta et al [44] where they revealed cure rates of Helicobacter 
pylori infection and healing rates of gastric/duodenal ulcers in patients treated with 
omeprazole in a gene-dose-effect manner. In addition, Study I further analyzed the 
concentration ratio of omeprazole and hydroxyomeprazole at 3 hours post dose and 
demonstrated a significant difference with no overlap among the three phenotype groups. 
The results suggest that the ratio could be used as an index of CYP2C19 activity 
following a single dose of omeprazole as a probe.  
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The suitability of omeprazole as a probe for CYP2C19 was further investigated in Study 
II with a population of 160 unrelated Swedish subjects. The validation also included seven 
subjects who had previously been phenotyped as PM by the mephenytoin method in order 
to cover the low incidence of PMs in the population studied. The utility of omeprazole as a 
probe drug for CYP2C19 phenotype was validated through comparisons with S-
mephenytoin hydroxylation phenotype and CYP2C19 genotype with respect to 
CYP2C19*2. The potential advantages of using omeprazole include 1) to address the 
concerns of using mephenytoin (unavailability and AEs); 2) to identify the subjects with 
very rapid hydroxylation based on a normal distribution of logMR of omeprazole; 3) 
might be useful as a dual substrate probe for both CYP2C19 and CYP3A4 activities.  
Study II is the first report to systematically assess the correlation between MR of 
omeprazole and S/R mephenytoin ratio in a population study. Considering the assay utility 
and convenience in practice, we used a single blood sample collected at 3 hours post dose 
as a measurement, which was selected based on the results from Study I. Spearman rank 
coefficient of correlation appeared to be low (0.63, p<0.001) between MR of omeprazole 
and S/R mephenytoin ratio, likely due to 18% of subjects with undetectable S-
mephenytoin value being assigned to S/R ratio of <0.05. In drug development process, 
omeprazole has already become a popular probe for CYP2C19 to assess the potential for 
drug-drug interaction. In most of the cases, series of blood samples are collected and 
AUCs of omeprazole are compared when dosed alone vs. in combination with the drug in 
question. Omeprazole can be used as a single probe and in cocktail studies as exemplified 
in Karolinska cocktail [37] and Cooperstown cocktail [147]. It is also successfully used as 
a dual substrate probe to evaluate induction of CYP2C19 and CYP3A4 in an efavirenzin 
study [148].  
We also used omeprazole as a dual substrate probe to estimate the induction potential of 
carbamazepine (CBZ) in Study III. CBZ is a known potent inducer of CYP3A4 that leads 
to the increase of clearance of CBZ and other drugs, for example oral conceptives [149]. 
Intuitively in our study, the mean AUC of omeprazole sulphone increased by 44% after 
omeprazole was administered concomitantly with CBZ, confirming that CBZ induced the 
formation of omeprazole sulphone mediated by CYP3A4. The ratio between the AUCs of 
omeprazole and sulphone decreased in all 5 subjects, but failed to show statistical 
significance (p=0.052). A large variation was found among the 5 patients, two (No 3 and 
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5) had dramatic reduction while others showed marginal effects. The small sample size, in 
addition to the variation, contributed largely to the low statistical power.  
The mechanism of enzyme induction caused by CBZ is less studied. One report from Luo 
and coworkers demonstrated CBZ weakly activated PXR and induced CYP3A4 activity as 
compared to rifampin in the human hepatocytes system [150]. Enzyme induction occurs 
when a ligand (CBZ in this case) binds to PXR or CAR, trigging RNA polymerase and 
mRNA transcription. The process could be less enzyme-specific and nonselective. 
Thereby the potential of CBZ for inducing CYP2C19 (hydroxylation of omeprazole) 
cannot be completely ruled out. In Study III, both AUCs of omeprazole and 
hydroxyomeprazole decreased by ~ 40% after coadministration with CBZ, resulting in an 
unchanged ratio between the parent and metabolite. The unchanged ratio suggested that 
CBZ had less or no effect on the formation of hydroxyomeprazole. This finding is actually 
in line with a number of studies reporting that the CBZ-mediated induction was found 
only with CYP3A4, CYP1A2, and P-glycoprotein [151], [150]. Since CYP3A4 and 
CYP2C19 are both involved in the primary and secondary metabolism of omeprazole as 
shown in Figure 3, the precise contribution of CYP3A4 induced by CBZ is, however, 
difficult to establish in our study.  
The oral anticoagulant warfarin is widely used for the treatment and prevention of 
thromboembolic disorders. Because it has a narrow therapeutic index, more than 10-fold 
interindividual variability in dose requirement, and multiple drug interactions, the clinical 
use of warfarin is challenging. The goal of pharmacogenetic testing is to aid clinicians in 
prescribing the right drug, with the right dose, at the right time. It is crucial that major 
functional allelic variants of CYP450 genes have been identified and included in the 
testing. In our earlier study where influence of CYP2C9 and CYP2C19 genetic 
polymorphisms on warfarin maintenance dose and metabolic clearance was evaluated, no 
significant effect of CYP2C19 genotypes on the clearance of unbound R-warfarin was 
found [141]. At the time of that study, the CYP2C19*17 allele had not yet been described, 
*17 alleles thus being classified as CYP2C19*1. Adding CYP2C19*17 genotyping to 
Study IV, we found a significant effect of CYP2C19 genotype on R-warfarin clearance, 
carriers of CYP2C19*17 having, on average, 32% higher clearance than carriers of 
CYP2C19*2. Study IV is to our knowledge the first study to include the gain-of-function 
allele in the analysis of the effect of CYP2C19 genotypes on the enantioselective 
pharmacokinetics and INR response of warfarin.  
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Patients with two functional CYP2C19*1 alleles had clearance values in between the 
CYP2C19*17 and CYP2C19*2 groups. Analysis of the*17 allele now allowed 
identification of a subgroup of patients with a predicted, on average, higher CYP2C19 
activity as compared to those carrying two CYP2C19*1 alleles. The improved prediction 
of the phenotype together with a larger patient population is a probable explanation to the 
observed significant effect of the genotype on R-warfarin clearance. Similar to this study, 
a significant effect of CYP2C19*17 on the pharmacokinetics of other CYP2C19 substrates 
has been shown, exemplified by omeprazole [152] and escitalopram [153] . 
It is interesting that using single nucleotide polymorphisms (SNPs) of loss-of-function 
alleles to predicate phenotypes for CYP2C19 seems to be well established compared to 
that of gain-of-function alleles (CYP2C19*17) where the controversy exists. A 
quantitative review by Li-Wan-Po A and colleagues displayed a large overlap in PK 
variables between carriers of *1/*1 and *1/*17 (similar results were also observed in our 
studies), and a modest effect between carriers of two gain-of function alleles 
(CYP2C19*17/*17) and two loss-of-function alleles (PMs). They questioned the utility of 
CYP2C19*17 in practice, suggesting to assign CYP2C19*17 homozygotes as EM rather 
than ultrarapid metabolisers (UM) [154].  
We also explored the CYP2C gene cluster haplotypes comprising the clinically most 
important CYP2C variants in Study IV. The frequencies higher than 10% in our Italian 
population were the same as those previously reported in Nordic populations [155]. 
Consistently, CYP2C19*17 was observed with an allele frequency of 17% and in strong 
linkage disequilibrium (LD) with CYP2C9*1 and CYP2C8*1. This result supports the 
observed correlation between CYP2C19*17 and R-warfarin clearance being independent 
from the other SNPs assessed in this study. Our analysis also confirmed the moderately 
strong LD between CYP2C8*3 and CYP2C9*2 (D’=0.78).  
In addition to the effect of CYP2C19 genotypes on R-warfarin clearance, an association 
with warfarin response was observed in Study IV, using INR/daily dose as a marker. 
CYP2C19 genotypes accounted for 7% of the variance in INR/daily dose. Genetic 
(VKORC1, CYP2C9, and CYP2C19) and non-genetic (age, gender, and body weight) 
covariates together explained 52% of the variability. Although the impact of CYP2C19 
genotypes was much smaller than that of VKORC1 and CYP2C9, it was nevertheless a 
significant factor. This finding is in line with the results of a recent PK/PD study [156], 
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suggesting that the R-enantiomer does indeed contribute to the anticoagulant effect of 
warfarin, based on both separate and combined administration of pure warfarin 
enantiomers. 
Meta-analysis is a powerful approach to give a thorough summary of several studies that 
have been conducted on the same topic. Study V is the first meta-analysis based on a 
systematic review of accumulated information that addresses the relationship between 
CYP2C19 genotypes and the exposure to citalopram or escitalopram. Compared to 
CYP2C19*1/*1, the exposure to (es)citalopram decreased significantly (p<0.0001), by 
36% (95% CI, 27-46%) in CYP2C19*17/*17. The precise estimate was derived from 
pooled data of 4 studies with 36 subjects homozygous for CYP2C19*17 and 237 
homozygous for CYP2C19*1 and assessed to be reliable based on the funnel plot 
asymmetry inspection. However, it is to be noted that there was a considerable 
heterogeneity among studies, indicating that the different results in individual studies may 
partly reflect differences in study populations and study designs. Taken together, our data 
from the meta-analysis demonstrates that homozygous carries of CYP2C19*17, on 
average, achieved 36% lower exposure to (es)citalopram, and may need higher doses to 
reach an exposure similar to that in subjects homozygous for CYP2C19*1 .  
Explicitly discussing the limitation would help interpret study findings appropriately. In 
our study, we could not account for the use of potential interacting drugs or the role of 
other CYP enzymes (such as CYP2D6) involved in citalopram or escitalopram 
metabolism. Co-medication was an exclusion criterion in the studies performed in healthy 
subjects, but was sometimes allowed in the patient studies. The drugs used concomitantly 
in patient studies were rarely specified clearly. Since drug interactions may influence the 
PK of citalopram or escitalopram, the possible impact of drug interactions cannot be 
excluded as a source of interindividual variability. 
Data extraction, categorization, and evaluation for eligibility are critical elements for an 
unbiased, transparent, and valid result. Recently, 3 meta-analyses with the same focus of 
CYP2C19 polymorphism on clinical outcome of clopidogrel treatment (published by 
Bauer et al [122], Holmes et al [123], and Jang et al [157], respectively) presented 
interesting outcomes. Three groups used almost identical searching strategy and study 
inclusion/exclusion criteria, so that the numbers of studies/patients included in the final 
analyses were similar, i.e. 15/19328, 16/20785, and 32/42016 in Bauer’s, Jang’s, and 
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Holmes’s study, respectively. The first two analyses have >75% of studies overlapping 
(12/15 vs. 12/16), but reached opposite conclusions. Holmes’ meta-analysis covered 100% 
and 94% of Bauer’s and Jang’s studies, respectively, demonstrated an overall negative 
result of cardiovascular events, supporting the conclusion of Bauer et al. When 
performing a systemic review, it is extremely challenging, and sometimes tricky, to assign 
grades to non-continuous variables in efficacy or safety outcomes during data extraction 
process.  
Interpretation of findings to provide appropriate implications for practice is another 
challenge. Based on our pooled analysis, we believe the results aid in understanding the 
interindividual variability in the exposure to citalopram and escitalopram in psychiatric 
patients and facilitate dose selection particularly for the homozygous carriers of loss-of-
functions (CYP2C19*2 or *3) and the gain-of-function (CYP2C19*17) alleles. The 
findings could improve individualization of citalopram or escitalopram therapy and could 
also be used for physiologically-based pharmacokinetic (PBPK) modeling as well as 
PK/PD modeling. However due to the difficulty in accurately measuring PD response in 
depression and anxiety disorders, a clear relationship of concentration-response cannot be 
simply established for citalopram and escitalopram as it can for dose-concentration 
relationships. In addition, the contribution of a specific enzyme may vary substantially 
between drugs and the quantitative influence of individual polymorphisms may 
theoretically be substrate specific. Therefore, it would be premature to extend the findings 
of (es)citalopram exposure in the specific allelic combination genotypes to a more general 
model of CYP2C19 activity prediction.  
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6 FUTURE PERSPECTIVES 
The clinical utility of genotyping and personalized medicine is generally believed to be 
favored when the drug has a narrow therapeutic window or is catalyzed predominantly 
by a polymorphic enzyme. Theoretically, genotyping the enzyme helps to predict 
therapeutic failures or AEs, and potentially speeds up the selection of optimal dosage 
range for individual patients. However, the promises of new technology are not 
translated into appreciable improvement in patient care as yet. The clinical uptake of 
pharmacogenetic or pharmacogenomic testing including genotype-guided prescribing is 
slow.  
To overcome the myriad obstacles, it requires joined-efforts from basic research, 
translational medicine, clinical laboratory medicine, clinical pharmacology, and 
regulatory oversight to move the new technology from bench to bedside. 
Basic research- A large body of information on the characterization of drug-mobilizing 
enzyme/polymorphisms has been generated. The gaps exist, however, in our knowledge 
regarding how to utilize the information to explain interindividual variability and to 
predict drug response outcomes. CYP genotype alone in many cases cannot be the 
answer. The complexity of biological systems and disease status should be considered. It 
is unclear if common diseases (e.g. diabetes, asthma, heart diseases, and cancer) could 
change the drug metabolism pattern through making up the genes of drug-metabolizing 
enzymes. Concerning pharmacogenetics and pharmacogenomics, it is necessary to study 
polymorphism in trans-acting genes or in the regulatory genes involved in 
transcriptional regulation, or receptor polymorphism. The “private” mutation, rare 
mutations in various populations and unknown rare polymorphism will add knowledge 
substantially to the current understanding.  
Clinical-laboratory-medicine/Translational medicine- Clinical laboratory research is an 
important piece between basic sciences and clinical practice. The transition from bench 
to bedside may not happen anywhere without the involvement of clinical labs with 
adequate knowledge, even though there are fruitful basic research and regulation. 
Concerning the predictive genotype for P450s in the clinic, it does not occur routinely 
for many reasons including medical, legal, economic, social, ethical, and organizational 
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issues [158]. Of these, lacking solid evidence for their advantage over current medical 
practice is the key barrier.  
To bridge the gap, randomized, large, conclusive, prospective studies showing 
improvement of drug efficacy following genotyping would be ideal but impractical. We 
cannot expect that such studies will in fact be performed for every new biomarker that 
will be discovered. A more pragmatic approach should be considered. In current clinical 
research, genotyping variants from the core and extended ADME gene list are 
recommended as exploratory objectives. For DDI and ADME studies, the genotyping 
tests are included as part of standard requirement and results are typically used within 
the study specific context. If there is significant impact of PM on the candidate drug, the 
information will be captured in its labeling. However, integrated use of the genotype 
data comprehensively and accumulatively across studies has not yet been a standard 
analysis. Since DDI and ADME are typically performed in healthy subjects, the disease 
related information is missing from the current practice.  
Validation of new biomarker/genotype requires tremendous effort, may need to include 
the in vitro novel methods, model-based simulation/prediction, tissue banks, and clinical 
trial designed with well defined inclusion and exclusion criteria including possible 
interactions with the drug studied. Generating data from clinical trials to demonstrate the 
associations between biomarkers and efficacy outcomes can be time consuming and 
costly. The innovative study designs, including adaptive clinical trials, provide 
considerable advantages. Typically, an adaptive study design would allow interim 
analyses in order to 1) stop/adjust patient accrual, cohorts or dose(s); 2) revise the 
hypotheses; and 3) stop the trial early for success, futility or harm. It is anticipated that 
use of adaptive study design could accelerate the turnaround time of a large clinical trial 
with multiple objectives/hypotheses. 
Other barriers in pharmacogenetic application include lack of education for health 
professions and the need to develop evidence-based clinical practice guidelines on the 
testing. 
Regulatory oversight- Regulatory structure needs to support the growth of 
pharmacogenetic/pharmacogenomic testing. According to the FDA, about 10% of labels 
for FDA-approved new drugs contain pharmacogenomic information [159]. It sounds 
like a small portion, but represents a substantial increase since the 1990s. Regulatory 
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agencies need to ensure the quality of products, especially when the results are used in 
making major medical decisions. As a matter of fact, some commercial laboratories 
(mainly in US) are broadly marketing their lab-based complicated genetic testing which 
they do not have the knowledge to fully interpret. The balance point between protecting 
patients and encouraging innovation can be a challenge for regulatory agencies. 
In Europe, there are no harmonized regulations or central regulators for medical 
diagnostics/biomarkers. The regulation can only occur at the member-state level. It is 
possible that clinical utility of approved tests may turn out to be no longer maintained at 
the current rate or level, whereas non-approved tests are used in practice [160]. In order 
to protect patients and give clinicians’ confidence on personalized medicine and 
pharmacogenetic/pharmacogenomic testing; it is more important than ever to call for 
regulatory support and revolution.  
To summarize, genotype-guided prescriptions, including algorithms, are being applied to 
a few cases and will hopefully increase in coming years. In order to bridge the gap 
between research and clinical practice, it will be crucial to accelerate testing the clinical 
validity of pharmacogenetic markers, to train medical professionals, and to deliver the 
clinical benefit of new biomarkers to patients. 
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